Jost Philipp |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2023

Originalarbeit (Zeitschrift)

** Koschmieder, S; Isfort, S; Wolf, D; Heidel, FH; Hochhaus, A; Schafhausen, P; Griesshammer, M; Wolleschak, D; Platzbecker, U; Dohner, K; Jost, PJ; Parmentier, S; Schaich, M; von Bubnoff, N; Stegelmann, F; Maurer, A; Crysandt, M; Gezer, D; Kortmann, M; Franklin, J; Frank, J; Hellmich, M; Brummendorf, TH Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
ANN HEMATOL. 2023; Doi: 10.1007/s00277-022-05080-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2022

Originalarbeit (Zeitschrift)

** Aftahy, AK; Barz, M; Lange, N; Baumgart, L; Thunstedt, C; Eller, MA; Wiestler, B; Bernhardt, D; Combs, SE; Jost, PJ; Delbridge, C; Liesche-Starnecker, F; Meyer, B; Gempt, J The Impact of Postoperative Tumor Burden on Patients With Brain Metastases
FRONT ONCOL. 2022; 12: 869764 Doi: 10.3389/fonc.2022.869764 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083 Doi: 10.1002/cam4.4675 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207 Doi: 10.3389/fimmu.2022.840207 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Baumgart, L; Barz, M; Delbridge, C; Aftahy, AK; Janssen, IK; Jost, PJ; Ryang, YM; Meyer, B; Gempt, J Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia
CURR ONCOL. 2022; 29(9): 6236-6244. Doi: 10.3390/curroncol29090490 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065 Doi: 10.1177/17588359221134065 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

** Heilig, CE; Lassmann, A; Mughal, SS; Mock, A; Pirmann, S; Teleanu, V; Renner, M; Andresen, C; Kohler, BC; Aybey, B; Bauer, S; Siveke, JT; Hamacher, R; Folprecht, G; Richter, S; Schrock, E; Brandts, CH; Ahrens, M; Hohenberger, P; Egerer, G; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Apostolidis, L; Jost, PJ; Westphalen, CB; Weichert, W; Keilholz, U; Klauschen, F; Beck, K; Winter, U; Richter, D; Mohrmann, L; Bitzer, M; Schulze-Osthoff, K; Brors, B; Mechtersheimer, G; Kreutzfeldt, S; Heining, C; Lipka, DB; Stenzinger, A; Schlenk, RF; Horak, P; Glimm, H; Hubschmann, D; Frohling, S Gene expression-based prediction of pazopanib efficacy in sarcoma
EUR J CANCER. 2022; 172: 107-118. Doi: 10.1016/j.ejca.2022.05.025
Web of Science PubMed FullText FullText_MUG

 

** Jahn, A; Rump, A; Widmann, TJ; Heining, C; Horak, P; Hutter, B; Paramasivam, N; Uhrig, S; Gieldon, L; Drukewitz, S; Kubler, A; Bermudez, M; Hackmann, K; Porrmann, J; Wagner, J; Arlt, M; Franke, M; Fischer, J; Kowalzyk, Z; William, D; Weth, V; Oster, S; Frohlich, M; Hullein, J; Gonzalez, CV; Kreutzfeldt, S; Mock, A; Heilig, CE; Lipka, DB; Mohrmann, L; Hanf, D; Oles, M; Teleanu, V; Allgauer, M; Ruhnke, L; Kutz, O; Knurr, A; Lassmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Buchhalter, I; Augustin, M; Aulitzky, WE; Hohenberger, P; Kroiss, M; Schirmacher, P; Schlenk, RF; Keilholz, U; Klauschen, F; Folprecht, G; Bauer, S; Siveke, JT; Brandts, CH; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Jost, PJ; Metzeler, KH; Bitzer, M; Schulze-Osthoff, K; von Kalle, C; Brors, B; Stenzinger, A; Weichert, W; Hubschmann, D; Frohling, S; Glimm, H; Schrock, E; Klink, B Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
ANN ONCOL. 2022; 33(11): 1186-1199. Doi: 10.1016/j.annonc.2022.07.008
Web of Science PubMed FullText FullText_MUG

 

** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353 Doi: 10.1016/j.clgc.2022.03.010
Web of Science PubMed FullText FullText_MUG

 

** Meinhardt, AL; Munkhbaatar, E; Höckendorf, U; Dietzen, M; Dechant, M; Anton, M; Jacob, A; Steiger, K; Weichert, W; Brcic, L; McGranahan, N; Branca, C; Kaufmann, T; Dengler, MA; Jost, PJ The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
Oncogene. 2022; 41(9):1376-1382 Doi: 10.1038/s41388-021-02161-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428 Doi: 10.3389/fcvm.2022.933428 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Reissig, TM; Uhrig, S; Jost, PJ; Luchini, C; Vicentini, C; Liffers, ST; Allgauer, M; Adsay, V; Scarpa, A; Lawlor, RT; Frohling, S; Stenzinger, A; Kloppel, G; Schildhaus, HU; Siveke, JT MCL1 as putative target in pancreatoblastoma
VIRCHOWS ARCH. 2022; Doi: 10.1007/s00428-022-03349-w [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645 Doi: 10.1055/a-1548-4847
Web of Science PubMed FullText FullText_MUG

 

** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463 Doi: 10.1038/s41416-021-01601-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Terbuch, A; Posch, F; Bauernhofer, T; Jost, PJ; Partl, R; Stranzl-Lawatsch, H; Baciarello, G; Fizazi, K; Giannatempo, P; Verzoni, E; Sweeney, C; Ravi, P; Tran, B; Basso, U; White, J; Vincenzi, B; Oing, C; Cutuli, HJ; Dieckmann, KP; Gamulin, M; Chovanec, M; Fankhauser, CD; Heidenreich, A; Mohamad, O; Thibault, C; Fischer, S; Gillessen, S, , International, Germ, Cell, Cancer, Collaborative, Group Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2022; 113(4):825-832 Doi: 10.1016/j.ijrobp.2022.03.021
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Dill, V; Wagner, CV; Keller, EC; Fernandez-Hernandez, FJ; Shoumariyeh, K; Odinius, TO; Buschhorn, L; Hauch, RT; Suren, C; Hecker, JS; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Höckendorf, U; Jilg, S; Branca, C; Vosberg, S; Jost, PJ Elevated RIPK3 correlates with disease burden in myelofibrosis.
Blood Adv. 2022; Doi: 10.1182/bloodadvances.2021006838
PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Balihodzic, A; Prinz, F; Dengler, MA; Calin, GA; Jost, PJ; Pichler, M Non-coding RNAs and ferroptosis: potential implications for cancer therapy.
Cell Death Differ. 2022; 29(6):1094-1106 Doi: 10.1038/s41418-022-00998-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jahn, SW; Jost, PJ Challenges in integrating molecular profiles into clinical cancer care
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00838-1
Web of Science FullText FullText_MUG

 

** Wahida, A; Buschhorn, L; Frohling, S; Jost, PJ; Schneeweiss, A; Lichter, P; Kurzrock, R The coming decade in precision oncology: six riddles
NAT REV CANCER. 2022; Doi: 10.1038/s41568-022-00529-3
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, P Inflammatory cell death acts as tumor suppressor in lung adenocarcinoma
INTERNIST. 2022; 63(SUPPL 3):338-339. [Oral Communication]
Web of Science

 

** Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557. Doi: 10.1016/j.annonc.2022.10.344 [Poster]
Web of Science FullText FullText_MUG

 

** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
MODERN PATHOL. 2022; 35(SUPPL 2): 613-613. [Poster]
Web of Science

 

** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
LAB INVEST. 2022; 102(SUPPL 1): 613-613. [Poster]
Web of Science

 

** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251. Doi: 10.1182/blood-2022-160087 [Oral Communication]
Web of Science FullText FullText_MUG

 

** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

 

** Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ; [Poster]
Web of Science

 

** Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202. [Poster]
Web of Science

 

2021

Originalarbeit (Zeitschrift)

** Barz, M; Aftahy, K; Janssen, I; Ryang, YM; Prokop, G; Combs, SE; Jost, PJ; Meyer, B; Gempt, J Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB).
CURR ONCOL. 2021; 28(5): 3891-3899. Doi: 10.3390/curroncol28050332 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Carlet, M; Völse, K; Vergalli, J; Becker, M; Herold, T; Arner, A; Senft, D; Jurinovic, V; Liu, WH; Gao, Y; Dill, V; Fehse, B; Baldus, CD; Bastian, L; Lenk, L; Schewe, DM; Bagnoli, JW; Vick, B; Schmid, JP; Wilhelm, A; Marschalek, R; Jost, PJ; Miething, C; Riecken, K; Schmidt-Supprian, M; Binder, V; Jeremias, I In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Nat Commun. 2021; 12(1): 5655 Doi: 10.1038/s41467-021-25963-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Horak, P; Heining, C; Kreutzfeldt, S; Hutter, B; Mock, A; Hüllein, J; Fröhlich, M; Uhrig, S; Jahn, A; Rump, A; Gieldon, L; Möhrmann, L; Hanf, D; Teleanu, V; Heilig, CE; Lipka, DB; Allgäuer, M; Ruhnke, L; Laßmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfütze, K; Geörg, C; Meißburger, B; Buchhalter, I; Augustin, M; Aulitzky, WE; Hohenberger, P; Kroiss, M; Schirmacher, P; Schlenk, RF; Keilholz, U; Klauschen, F; Folprecht, G; Bauer, S; Siveke, JT; Brandts, CH; Kindler, T; Boerries, M; Illert, AL; von, Bubnoff, N; Jost, PJ; Spiekermann, K; Bitzer, M; Schulze-Osthoff, K; von, Kalle, C; Klink, B; Brors, B; Stenzinger, A; Schröck, E; Hübschmann, D; Weichert, W; Glimm, H; Fröhling, S Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Cancer Discov. 2021; 11(11): 2780-2795. Doi: 10.1158/2159-8290.CD-21-0126
Web of Science PubMed FullText FullText_MUG

 

** Huemer, M; Jahn-Kuch, D; Hofmann, G; Andritsch, E; Farkas, C; Schaupp, W; Masel, EK; Jost, PJ; Pichler, M Trends and Patterns in the Public Awareness of Palliative Care, Euthanasia, and End-of-Life Decisions in 3 Central European Countries Using Big Data Analysis From Google: Retrospective Analysis.
J Med Internet Res. 2021; 23(9): e28635 Doi: 10.2196/28635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Liotta, L; Lange, S; Maurer, HC; Olive, KP; Braren, R; Pfarr, N; Burger, S; Muckenhuber, A; Jesinghaus, M; Steiger, K; Weichert, W; Friess, H; Schmid, R; Algül, H; Jost, PJ; Ramser, J; Fischer, C; Quante, AS; Reichert, M; Quante, M PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer.
JCI Insight. 2021; 6(8): Doi: 10.1172/jci.insight.141532 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930 Doi: 10.1177/17588359211039930 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Odinius, TO; Buschhorn, L; Wagner, C; Hauch, RT; Dill, V; Dechant, M; Buck, MC; Shoumariyeh, K; Moog, P; Schwaab, J; Reiter, A; Brockow, K; Götze, K; Bassermann, F; Höckendorf, U; Branca, C; Jost, PJ; Jilg, S Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
J CANCER RES CLIN. 2021; Doi: 10.1007/s00432-021-03827-9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Pichler, T; Rohrmoser, A; Letsch, A; Westphalen, CB; Keilholz, U; Heinemann, V; Lamping, M; Jost, PJ; Riedmann, K; Herschbach, P; Goerling, U Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?
Support Care Cancer. 2021; 29(4):2171-2178 Doi: 10.1007/s00520-020-05692-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Suppan, C; Posch, F; Mueller, HD; Mischitz, N; Steiner, D; Klocker, EV; Setaffy, L; Bargfrieder, U; Hammer, R; Hauser, H; Jost, PJ; Dandachi, N; Lax, S; Balic, M Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
Cancers (Basel). 2021; 13(10): Doi: 10.3390/cancers13102492 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Wahida, A; Müller, M; Hiergeist, A; Popper, B; Steiger, K; Branca, C; Tschurtschenthaler, M; Engleitner, T; Donakonda, S; De, Coninck, J; Öllinger, R; Pfautsch, MK; Müller, N; Silva, M; Usluer, S; Oberg, ET; Böttcher, JP; Pfarr, N; Anton, M; Slotta-Huspenina, JB; Nerlich, AG; Madl, T; Basic, M; Bleich, A; Berx, G; Ruland, J; Knolle, PA; Rad, R; Adolph, TE; Vandenabeele, P; Kanegane, H; Gessner, A; Jost, PJ; Yabal, M XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells.
Sci Immunol. 2021; 6(65): eabf7235 Doi: 10.1126/sciimmunol.abf7235
Web of Science PubMed FullText FullText_MUG

 

** Wang, X; Ros, U; Agrawal, D; Keller, EC; Slotta-Huspenina, J; Dill, V; Shen, B; Shi, R; Herold, T; Belka, C; Mishra, R; Bassermann, F; Garcia-Saez, AJ; Jost, PJ MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF.
CELL DEATH DIFFER. 2021; Doi: 10.1038/s41418-021-00811-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Kricheldorf, K; Döhner, K; Stegelmann, F; Jost, PJ; Lang, F; Radsak, M; Hansen, R; Heuer, V; Röhrig, R; Brümmendorf, TH; Koschmieder, S; Isfort, S Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.
LEUKEMIA RES. 2021; 110: 106646 Doi: 10.1016/j.leukres.2021.106646 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Smolle, E; Taucher, V; Lindenmann, J; Jost, PJ; Pichler, M Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Cancers (Basel). 2021; 13(4): Doi: 10.3390/cancers13040699 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Korrektur

** Wang, X; Ros, U; Agrawal, D; Keller, EC; Slotta-Huspenina, J; Dill, V; Shen, B; Shi, R; Herold, T; Belka, C; Mishra, R; Bassermann, F; Garcia-Saez, AJ; Jost, PJ Correction: MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF.
Cell Death Differ. 2021; Doi: 10.1038/s41418-021-00826-8 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; Branca, C; McGranahan, N; Jost, PJ RIPK3 downregulation in lung cancer alters the tumor immune micro-environment supporting tumor progression
ONCOL RES TREAT. 2021; 44: 51-52.
Web of Science

 

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, PJ Necroptosis establishes an inflammatory tumor immune microenvironment acting as tumor suppressor in lung adenocarcinoma
ANN ONCOL. 2021; 32: S945-S945. Doi: 10.1016/j.annonc.2021.08.1788 [Poster]
Web of Science FullText FullText_MUG

 

** Dill, V; Wagner, C; Keller, E; Shoumariyeh, K; Odinius, T; Buschhorn, L; Suren, C; Hecker, J; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Hockendorf, U; Branca, C; Jilg, S; Jost, PJ RIPK3-dependent necroinflammation as a disease promoting mechanism in human myelofibrosis
ONCOL RES TREAT. 2021; 44: 161-161.
Web of Science

 

** Jost, PJ; Munkhbaatar, E; Dietzen, M; Branca, C; McGranahan, N Clonal evolution in lung cancer highlights MCL-1 gains as therapeutic target in lung adenocarcinoma
J THORAC ONCOL. 2021; 16(4):S704-S704. [Poster]
Web of Science

 

** Lorch, M; Pfirrmann, M; Fabisch, C; Oberle, L; Kohn, D; Kohlbrenner, K; Brummendorf, TH; Burchert, A; Krause, SW; le Coutre, P; Hanel, M; Franke, GN; Stegelmann, F; Radsak, M; Kunzmann, V; Jost, PJ; Hofmann, WK; Hochhaus, A; Saussele, S Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population
ONCOL RES TREAT. 2021; 44: 71-72.
Web of Science

 

** Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229. [Poster]
Web of Science

 

2020

Originalarbeit (Zeitschrift)

** Dill, V; Kauschinger, J; Hauch, RT; Buschhorn, L; Odinius, TO; Müller-Thomas, C; Mishra, R; Kyncl, MC; Schmidt, B; Prodinger, PM; Hempel, D; Bellos, F; Höllein, A; Kern, W; Haferlach, T; Slotta-Huspenina, J; Bassermann, F; Peschel, C; Götze, KS; Waizenegger, IC; Höckendorf, U; Jost, PJ; Jilg, S Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Eur J Haematol. 2020; 104(2):125-137 Doi: 10.1111/ejh.13354 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jayavelu, AK; Schnöder, TM; Perner, F; Herzog, C; Meiler, A; Krishnamoorthy, G; Huber, N; Mohr, J; Edelmann-Stephan, B; Austin, R; Brandt, S; Palandri, F; Schröder, N; Isermann, B; Edlich, F; Sinha, AU; Ungelenk, M; Hübner, CA; Zeiser, R; Rahmig, S; Waskow, C; Coldham, I; Ernst, T; Hochhaus, A; Jilg, S; Jost, PJ; Mullally, A; Bullinger, L; Mertens, PR; Lane, SW; Mann, M; Heidel, FH Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Nature. 2020; 588(7836):157-163 Doi: 10.1038/s41586-020-2968-3
Web of Science PubMed FullText FullText_MUG

 

** Joensuu, H; Eriksson, M; Sundby Hall, K; Reichardt, A; Hermes, B; Schütte, J; Cameron, S; Hohenberger, P; Jost, PJ; Al-Batran, SE; Lindner, LH; Bauer, S; Wardelmann, E; Nilsson, B; Kallio, R; Jaakkola, P; Junnila, J; Alvegård, T; Reichardt, P Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
JAMA Oncol. 2020; 6(8):1241-1246 Doi: 10.1001/jamaoncol.2020.2091 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jost, PJ; Vucic, D Regulation of Cell Death and Immunity by XIAP.
JACC-CARDIOVASC INTE. 2020; 13(15): a036426 Doi: 10.1101/cshperspect.a036426
Web of Science FullText FullText_MUG

 

** Lampl, S; Janas, MK; Donakonda, S; Brugger, M; Lohr, K; Schneider, A; Manske, K; Sperl, LE; Kläger, S; Küster, B; Wettmarshausen, J; Müller, C; Laschinger, M; Hartmann, D; Hüser, N; Perocchi, F; Schmitt-Kopplin, P; Hagn, F; Zender, L; Hornung, V; Borner, C; Pichlmair, A; Kashkar, H; Klingenspor, M; Prinz, M; Schreiner, S; Conrad, M; Jost, PJ; Zischka, H; Steiger, K; Krönke, M; Zehn, D; Protzer, U; Heikenwälder, M; Knolle, PA; Wohlleber, D Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
J Hepatol. 2020; 73(6):1347-1359 Doi: 10.1016/j.jhep.2020.06.026
Web of Science PubMed FullText FullText_MUG

 

** Munkhbaatar, E; Dietzen, M; Agrawal, D; Anton, M; Jesinghaus, M; Boxberg, M; Pfarr, N; Bidola, P; Uhrig, S; Höckendorf, U; Meinhardt, AL; Wahida, A; Heid, I; Braren, R; Mishra, R; Warth, A; Muley, T; Poh, PSP; Wang, X; Fröhling, S; Steiger, K; Slotta-Huspenina, J; van, Griensven, M; Pfeiffer, F; Lange, S; Rad, R; Spella, M; Stathopoulos, GT; Ruland, J; Bassermann, F; Weichert, W; Strasser, A; Branca, C; Heikenwalder, M; Swanton, C; McGranahan, N; Jost, PJ MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.
Nat Commun. 2020; 11(1):4527 Doi: 10.1038/s41467-020-18372-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Safi, S; Yamauchi, Y; Hoffmann, H; Weichert, W; Jost, PJ; Winter, H; Muley, T; Beckhove, P Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer.
Cancers (Basel). 2020; 12(12): Doi: 10.3390/cancers12123496 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Scherr, AL; Mock, A; Gdynia, G; Schmitt, N; Heilig, CE; Korell, F; Rhadakrishnan, P; Hoffmeister, P; Metzeler, KH; Schulze-Osthoff, K; Illert, AL; Boerries, M; Trojan, J; Waidmann, O; Falkenhorst, J; Siveke, J; Jost, PJ; Bitzer, M; Malek, NP; Vecchione, L; Jelas, I; Brors, B; Glimm, H; Stenzinger, A; Grekova, SP; Gehrig, T; Schulze-Bergkamen, H; Jäger, D; Schirmacher, P; Heikenwalder, M; Goeppert, B; Schneider, M; Fröhling, S; Köhler, BC Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Cell Death Dis. 2020; 11(10):875 Doi: 10.1038/s41419-020-03092-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Schwaab, J; Naumann, N; Luebke, J; Jawhar, M; Somervaille, TCP; Williams, MS; Frewin, R; Jost, PJ; Lichtenegger, FS; La Rosée, P; Storch, N; Haferlach, T; Horny, HP; Fabarius, A; Haferlach, C; Burchert, A; Hofmann, WK; Cross, NCP; Hochhaus, A; Reiter, A; Metzgeroth, G Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Am J Hematol. 2020; 95(7):824-833 Doi: 10.1002/ajh.25825 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Crodel, CC; Jentsch-Ullrich, K; Koschmieder, S; Kämpfe, D; Griesshammer, M; Döhner, K; Jost, PJ; Wolleschak, D; Isfort, S; Stegelmann, F; Jilg, S; Hofmann, V; Auteri, G; Rachow, T; Ernst, P; Brioli, A; von Lilienfeld-Toal, M; Hochhaus, A; Palandri, F; Heidel, FH Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Leukemia. 2020; 34(7):1949-1953 Doi: 10.1038/s41375-020-0890-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Jost, PJ; Vucic, D Regulation of Cell Death and Immunity by XIAP.
Cold Spring Harb Perspect Biol. 2020; 12(8): Doi: 10.1101/cshperspect.a036426 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Korrektur

** Crodel, CC; Jentsch-Ullrich, K; Koschmieder, S; Kämpfe, D; Griesshammer, M; Döhner, K; Jost, PJ; Wolleschak, D; Isfort, S; Stegelmann, F; Jilg, S; Hofmann, V; Auteri, G; Rachow, T; Ernst, P; Brioli, A; von Lilienfeld-Toal, M; Hochhaus, A; Palandri, F; Heidel, FH Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Leukemia. 2020; 34(11): 3106-3106. Doi: 10.1038/s41375-020-0970-2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Knop, J; Spilgies, LM; Rufli, S; Reinhart, R; Vasilikos, L; Yabal, M; Owsley, E; Jost, PJ; Marsh, RA; Wajant, H; Robinson, MD; Kaufmann, T; Wong, WW Correction: TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.
Cell Death Dis. 2020; 11(1):56-56 Doi: 10.1038/s41419-020-2261-2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Munkhbaatar, E; Dietzen, M; McGranahan, N; Jost, PJ Dissecting clonal evolution in lung adenocarcinoma identified chromosomal gains on 1q21 implying novel therapeutic targets.
ONCOL RES TREAT. 2020; 43(SUPPL 4):135-135. [Onlinepräsentation]
Web of Science

 

Kommentar

** Hähnel, T; Baldow, C; Guilhot, J; Guilhot, F; Saussele, S; Mustjoki, S; Jilg, S; Jost, PJ; Dulucq, S; Mahon, FX; Roeder, I; Fassoni, AC; Glauche, I Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Cancer Res. 2020; 80(11):2394-2406 Doi: 10.1158/0008-5472.CAN-19-2175
Web of Science PubMed FullText FullText_MUG

 

2019

Originalarbeit (Zeitschrift)

** Bidola, P; Martins de Souza E Silva, J; Achterhold, K; Munkhbaatar, E; Jost, PJ; Meinhardt, AL; Taphorn, K; Zdora, MC; Pfeiffer, F; Herzen, J A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography.
Sci Rep. 2019; 9(1):1325-1325 Doi: 10.1038/s41598-018-37394-w [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jilg, S; Hauch, RT; Kauschinger, J; Buschhorn, L; Odinius, TO; Dill, V; Müller-Thomas, C; Herold, T; Prodinger, PM; Schmidt, B; Hempel, D; Bassermann, F; Peschel, C; Götze, KS; Höckendorf, U; Haferlach, T; Jost, PJ Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Exp Hematol Oncol. 2019; 8(10):9-9 Doi: 10.1186/s40164-019-0133-1 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jilg, S; Rassner, M; Maier, J; Waldeck, S; Kehl, V; Follo, M; Philipp, U; Sauter, A; Specht, K; Mitschke, J; Lange, T; Bauer, S; Jost, PJ; Peschel, C; Duyster, J; Gaiser, T; Hohenberger, P; von Bubnoff, N Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Int J Cancer. 2019; 145(8):2292-2303 Doi: 10.1002/ijc.32282
Web of Science PubMed FullText FullText_MUG

 

** Knop, J; Spilgies, LM; Rufli, S; Reinhart, R; Vasilikos, L; Yabal, M; Owsley, E; Jost, PJ; Marsh, RA; Wajant, H; Robinson, MD; Kaufmann, T; Wong, WW TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.
Cell Death Dis. 2019; 10(10):700-700 Doi: 10.1038/s41419-019-1938-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Müller, N; Fischer, JC; Yabal, M; Haas, T; Poeck, H; Jost, PJ XIAP deficiency in hematopoietic recipient cells drives donor T-cell activation and GvHD in mice.
Eur J Immunol. 2019; 49(3):504-507 Doi: 10.1002/eji.201847818
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Jost, PJ; Höckendorf, U Necroinflammation emerges as a key regulator of hematopoiesis in health and disease.
Cell Death Differ. 2019; 26(1):53-67 Doi: 10.1038/s41418-018-0194-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Riedmann, K; Bassermann, F; Jost, PJ [Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544 Doi: 10.1007/s00108-019-0577-8
Web of Science PubMed FullText FullText_MUG

 

Fallbericht

** Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Steiger, K; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Eur J Haematol. 2019; 102(5):437-441 Doi: 10.1111/ejh.13218 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Horak, P; Heining, C; Kreutzfeldt, S; Heilig, CE; Mohrmann, L; Gieldon, L; Frohlich, M; Uhrig, S; Hubschmann, D; Beck, K; Richter, D; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Klauschen, F; Ochsenreither, S; Folprecht, G; Siveke, J; Bauer, S; Kindler, T; Brandts, C; Borries, M; von Bubnoff, N; Spiekermann, K; Jost, PJ; Schulze-Osthoff, K; Bitzer, M; Schirmacher, P; von Kalle, C; Schlenk, R; Klink, B; Flutter, B; Weichert, W; Stenzinger, A; Schrock, E; Brors, B; Glimm, H; Frohling, S Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium
CANCER RES. 2019; 79(13): Doi: 10.1158/1538-7445.AM2019-468
Web of Science FullText FullText_MUG

 

** Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W Detection of the mutation burden status and microsatellite instability by targeted next generation sequencing applying a large gene panel
VIRCHOWS ARCH. 2019; 475: S104-S104.
Web of Science

 

2018

Originalarbeit (Zeitschrift)

** Lier, A; Penzel, R; Heining, C; Horak, P; Frohlich, M; Uhrig, S; Budczies, J; Kirchner, M; Volckmar, AL; Hutter, B; Kreutzfeldt, S; Endris, V; Richter, D; Wolf, S; Pfutze, K; Neumann, O; Buchhalter, I; de Oliveira, CMM; Singer, S; Leichsenring, J; Herpel, E; Klauschen, F; Jost, PJ; Metzeler, KH; Schulze-Osthoff, K; Kopp, HG; Kindler, T; Rieke, DT; Lamping, M; Brandts, C; Falkenhorst, J; Bauer, S; Schrock, E; Folprecht, G; Boerries, M; von Bubnoff, N; Weichert, W; Brors, B; Lichter, P; von Kalle, C; Schirmacher, P; Glimm, H; Frohling, S; Stenzinger, A Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience
JCO PRECIS ONCOL. 2018; 2: Doi: 10.1200/PO.18.00171
Web of Science FullText FullText_MUG

 

** Reidel, V; Kauschinger, J; Hauch, RT; Müller-Thomas, C; Nadarajah, N; Burgkart, R; Schmidt, B; Hempel, D; Jacob, A; Slotta-Huspenina, J; Höckendorf, U; Peschel, C; Kern, W; Haferlach, T; Götze, KS; Jilg, S; Jost, PJ Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Oncotarget. 2018; 9(25):17270-17281 Doi: 10.18632/oncotarget.24775 [OPEN ACCESS]
PubMed FullText FullText_MUG

 

** Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Dietz, C; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Müller, M; Pagoni, M; Dimou, M; Dengler, J; Waller, CF; Brümmendorf, TH; Herbst, R; Burchert, A; Janβen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Büschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk. 2018; 18(4):266-271 Doi: 10.1016/j.clml.2018.02.004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Galluzzi, L; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Agostinis, P; Alnemri, ES; Altucci, L; Amelio, I; Andrews, DW; Annicchiarico-Petruzzelli, M; Antonov, AV; Arama, E; Baehrecke, EH; Barlev, NA; Bazan, NG; Bernassola, F; Bertrand, MJM; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Boya, P; Brenner, C; Campanella, M; Candi, E; Carmona-Gutierrez, D; Cecconi, F; Chan, FK; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Cohen, GM; Conrad, M; Cubillos-Ruiz, JR; Czabotar, PE; D'Angiolella, V; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, KM; DeBerardinis, RJ; Deshmukh, M; Di Daniele, N; Di Virgilio, F; Dixit, VM; Dixon, SJ; Duckett, CS; Dynlacht, BD; El-Deiry, WS; Elrod, JW; Fimia, GM; Fulda, S; García-Sáez, AJ; Garg, AD; Garrido, C; Gavathiotis, E; Golstein, P; Gottlieb, E; Green, DR; Greene, LA; Gronemeyer, H; Gross, A; Hajnoczky, G; Hardwick, JM; Harris, IS; Hengartner, MO; Hetz, C; Ichijo, H; Jäättelä, M; Joseph, B; Jost, PJ; Juin, PP; Kaiser, WJ; Karin, M; Kaufmann, T; Kepp, O; Kimchi, A; Kitsis, RN; Klionsky, DJ; Knight, RA; Kumar, S; Lee, SW; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lowe, SW; Luedde, T; Lugli, E; MacFarlane, M; Madeo, F; Malewicz, M; Malorni, W; Manic, G; Marine, JC; Martin, SJ; Martinou, JC; Medema, JP; Mehlen, P; Meier, P; Melino, S; Miao, EA; Molkentin, JD; Moll, UM; Muñoz-Pinedo, C; Nagata, S; Nuñez, G; Oberst, A; Oren, M; Overholtzer, M; Pagano, M; Panaretakis, T; Pasparakis, M; Penninger, JM; Pereira, DM; Pervaiz, S; Peter, ME; Piacentini, M; Pinton, P; Prehn, JHM; Puthalakath, H; Rabinovich, GA; Rehm, M; Rizzuto, R; Rodrigues, CMP; Rubinsztein, DC; Rudel, T; Ryan, KM; Sayan, E; Scorrano, L; Shao, F; Shi, Y; Silke, J; Simon, HU; Sistigu, A; Stockwell, BR; Strasser, A; Szabadkai, G; Tait, SWG; Tang, D; Tavernarakis, N; Thorburn, A; Tsujimoto, Y; Turk, B; Vanden Berghe, T; Vandenabeele, P; Vander Heiden, MG; Villunger, A; Virgin, HW; Vousden, KH; Vucic, D; Wagner, EF; Walczak, H; Wallach, D; Wang, Y; Wells, JA; Wood, W; Yuan, J; Zakeri, Z; Zhivotovsky, B; Zitvogel, L; Melino, G; Kroemer, G Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Cell Death Differ. 2018; 25(3):486-541 Doi: 10.1038/s41418-017-0012-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fallbericht

** Moog, P; Jost, PJ; Büttner-Herold, M Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.
BMC Nephrol. 2018; 19(1):106-106 Doi: 10.1186/s12882-018-0904-7 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jilg, S; Hauch, RT; Wahida, A; Kauschinger, J; Buschhorn, L; Odinius, T; Reidel, V; Schmid, B; Hempel, D; Hollein, A; Peschel, C; Bassermann, F; Slotta-Huspenina, J; Hockendorf, U; Jost, PJ Stage-dependent role of pro-necroptotic RIPK1/3 in patients with MDS and CMML
ONCOL RES TREAT. 2018; 41: 94-94.
Web of Science

 

** Muller, N; Fischer, J; Haas, T; Poeck, H; Yabal, M; Jost, PJ RIPK3 as an essential mediator of inflammation and cell death which facilitates IL-17 induction in innate and adaptive T lymphocyte subsets
EUR J IMMUNOL. 2018; 48: 121-121.
Web of Science

 

** Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
ANN ONCOL. 2018; 29:
Web of Science

 

2017

Originalarbeit (Zeitschrift)

** Boege, Y; Malehmir, M; Healy, ME; Bettermann, K; Lorentzen, A; Vucur, M; Ahuja, AK; Böhm, F; Mertens, JC; Shimizu, Y; Frick, L; Remouchamps, C; Mutreja, K; Kähne, T; Sundaravinayagam, D; Wolf, MJ; Rehrauer, H; Koppe, C; Speicher, T; Padrissa-Altés, S; Maire, R; Schattenberg, JM; Jeong, JS; Liu, L; Zwirner, S; Boger, R; Hüser, N; Davis, RJ; Müllhaupt, B; Moch, H; Schulze-Bergkamen, H; Clavien, PA; Werner, S; Borsig, L; Luther, SA; Jost, PJ; Weinlich, R; Unger, K; Behrens, A; Hillert, L; Dillon, C; Di Virgilio, M; Wallach, D; Dejardin, E; Zender, L; Naumann, M; Walczak, H; Green, DR; Lopes, M; Lavrik, I; Luedde, T; Heikenwalder, M; Weber, A A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.
Cancer Cell. 2017; 32(3):342-359 Doi: 10.1016/j.ccell.2017.08.010 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Höckendorf, U; Yabal, M; Jost, PJ Killing AML: RIPK3 leads the way.
Cell Cycle. 2017; 16(1):3-4 Doi: 10.1080/15384101.2016.1232069 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Holch, JW; Metzeler, KH; Jung, A; Riedmann, K; Jost, PJ; Weichert, W; Kirchner, T; Heinemann, V; Westphalen, CB Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Eur J Cancer. 2017; 82(3):72-79 Doi: 10.1016/j.ejca.2017.05.034
Web of Science PubMed FullText FullText_MUG

 

** Lawlor, KE; Feltham, R; Yabal, M; Conos, SA; Chen, KW; Ziehe, S; Graß, C; Zhan, Y; Nguyen, TA; Hall, C; Vince, AJ; Chatfield, SM; D'Silva, DB; Pang, KC; Schroder, K; Silke, J; Vaux, DL; Jost, PJ; Vince, JE XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1β Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation.
Cell Rep. 2017; 20(3):668-682 Doi: 10.1016/j.celrep.2017.06.073 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Hockendorf, U; Yabal, M; Jost, PJ RIPK3-Dependent Cell Death and Differentiation of Leukemia Initiating Cells Restrict Myeloid Leukemogenesis
ANN HEMATOL. 2017; 96: S50-S50.
Web of Science

 

** Jilg, S; Kauschinger, J; Hauch, RT; Reidel, V; Muller-Thomas, C; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, KS; Jost, PJ Inhibition of Polo-like Kinase 1 effectively induces cell death in MDS, CMML-1/-2 and sAML while sparing the healthy heamatopoiesis
ONCOL RES TREAT. 2017; 40: 179-179.
Web of Science

 

** Jilg, S; Reidel, V; Kauschinger, J; Muller-Thomas, C; Hauch, R; Schauwecker, J; Burkhard, S; Hockendorf, U; Peschel, C; Kern, W; Haferlach, T; Slotta-Huspenina, J; Gotze, KS; Jost, PJ BCL-2 INHIBITION BY ABT-199 POTENTLY INDUCES CELL DEATH IN MDS PROGENITORS DESPITE HIGH-RISK MUTATIONS IN ASXL1, RUNX1, TP53 OR EZH2
LEUKEMIA RES. 2017; 55: S156-S156. Doi: 10.1016/S0145-2126(17)30385-5
Web of Science FullText FullText_MUG

 

** Jost, PJ; Yabal, M; Hockendorf, U Inflammation and cell death controls AML development, phenotype and outcome
ONCOL RES TREAT. 2017; 40: 54-54.
Web of Science

 

** Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Pagoni, M; Dimou, M; Dengler, J; Waller, C; Brummendorf, TH; Herbst, R; Burchert, A; Janssen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Buschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
HAEMATOLOGICA. 2017; 102: 74-74. [OPEN ACCESS]
Web of Science

 

2016

Originalarbeit (Zeitschrift)

** Engel, K; Rudelius, M; Slawska, J; Jacobs, L; Ahangarian Abhari, B; Altmann, B; Kurutz, J; Rathakrishnan, A; Fernández-Sáiz, V; Brunner, A; Targosz, BS; Loewecke, F; Gloeckner, CJ; Ueffing, M; Fulda, S; Pfreundschuh, M; Trümper, L; Klapper, W; Keller, U; Jost, PJ; Rosenwald, A; Peschel, C; Bassermann, F USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.
EMBO Mol Med. 2016; 8(8):851-862 Doi: 10.15252/emmm.201506047 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Höckendorf, U; Yabal, M; Herold, T; Munkhbaatar, E; Rott, S; Jilg, S; Kauschinger, J; Magnani, G; Reisinger, F; Heuser, M; Kreipe, H; Sotlar, K; Engleitner, T; Rad, R; Weichert, W; Peschel, C; Ruland, J; Heikenwalder, M; Spiekermann, K; Slotta-Huspenina, J; Groß, O; Jost, PJ RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Cancer Cell. 2016; 30(1):75-91 Doi: 10.1016/j.ccell.2016.06.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Hrdinka, M; Fiil, BK; Zucca, M; Leske, D; Bagola, K; Yabal, M; Elliott, PR; Damgaard, RB; Komander, D; Jost, PJ; Gyrd-Hansen, M CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling.
Cell Rep. 2016; 14(12):2846-2858 Doi: 10.1016/j.celrep.2016.02.062 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jilg, S; Reidel, V; Müller-Thomas, C; König, J; Schauwecker, J; Höckendorf, U; Huberle, C; Gorka, O; Schmidt, B; Burgkart, R; Ruland, J; Kolb, HJ; Peschel, C; Oostendorp, RA; Götze, KS; Jost, PJ Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Leukemia. 2016; 30(1):112-123 Doi: 10.1038/leu.2015.179
Web of Science PubMed FullText FullText_MUG

 

** Spinner, S; Crispatzu, G; Yi, JH; Munkhbaatar, E; Mayer, P; Höckendorf, U; Müller, N; Li, Z; Schader, T; Bendz, H; Hartmann, S; Yabal, M; Pechloff, K; Heikenwalder, M; Kelly, GL; Strasser, A; Peschel, C; Hansmann, ML; Ruland, J; Keller, U; Newrzela, S; Herling, M; Jost, PJ Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Leukemia. 2016; 30(7):1520-1530 Doi: 10.1038/leu.2016.49
Web of Science PubMed FullText FullText_MUG

 

** Wicki, S; Gurzeler, U; Wei-Lynn Wong, W; Jost, PJ; Bachmann, D; Kaufmann, T Loss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils.
Cell Death Dis. 2016; 7(10):e2422-e2422 Doi: 10.1038/cddis.2016.311 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Fernández-Marrero, Y; Spinner, S; Kaufmann, T; Jost, PJ Survival control of malignant lymphocytes by anti-apoptotic MCL-1.
Leukemia. 2016; 30(11):2152-2159 Doi: 10.1038/leu.2016.213
Web of Science PubMed FullText FullText_MUG

 

Editorial

** Höckendorf, U; Yabal, M; Jost, PJ RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs.
Oncotarget. 2016; 7(36):57483-57484 Doi: 10.18632/oncotarget.11195 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Ahmadova, G; Kreil, S; Jost, PJ; Keller, P; Wolfensberger, N; Maschke, A; Schonberger, B; Haferlach, T; Schwaab, J; Naumann, N; Jahwar, M; Cross, NCP; Fabarius, A; Hofmann, WK; Haferlach, C; Reiter, A; Metzgeroth, G Clinical characteristics and treatment with tyrosine kinase inhibitors in four patients with ETV6-ABL1 positive eosinophilia-associated myeloproliferative neoplasms
ONCOL RES TREAT. 2016; 39: 232-233.
Web of Science

 

** Glauche, I; Liebscher, H; Baldow, C; Kuhn, M; Schulze, P; Haehnel, T; Voskanyan, A; Guilhot, J; Dulucq, S; von Bubnoff, N; Saussele, S; Mustjoki, S; Jost, PJ; Guilhot, F; Mahon, FX; Roeder, I A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.3099.3099 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Hockendorf, U; Monica, Y; Peschel, C; Jost, PJ Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.2856.2856 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Jilg, S; Kauschinger, J; Reidel, V; Muller-Thomas, C; Hauch, R; Schauwecker, J; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, K; Jost, PJ Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.4297.4297 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Reiter, A; Ahmadova, G; Jawhar, M; Virchis, A; Somervaille, T; Williams, M; Schonberger, B; Frewin, R; Jost, PJ; Maschke, A; Keller, P; Haferlach, T; Naumann, N; Schwaab, J; Fabarius, A; Hofmann, WK; Haferlach, C; Cross, NCP; Metzgeroth, G Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.3114.3114 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Saussele, S; Mahon, FX; Guilhot, J; Dengler, J; Waller, CT; Brummendorf, TH; Herbst, R; Burchert, A; Goebeler, ME; Freunek, G; Prummer, O; Jost, PJ; Prange-Krex, G; Illmer, T; Janzen, V; Schafhausen, P; Klausmann, M; Kiani, A; Eckert, R; de Wit, M; Janssen, C; Muller, MC; Hochhaus, A; Richter, J; Pfirrmann, M Stopping tyrosine kinase inhibitors in a large cohort of European chronic myeloid leukemia (CML) patients: results of the EURO-SKI trial
ONCOL RES TREAT. 2016; 39: 209-209.
Web of Science

 

2015

Originalarbeit (Zeitschrift)

** Yabal, M; Jost, PJ XIAP as a regulator of inflammatory cell death: the TNF and RIP3 angle.
Mol Cell Oncol. 2015; 2(1):e964622-e964622 Doi: 10.4161/23723548.2014.964622 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Galluzzi, L; Bravo-San Pedro, JM; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Alnemri, ES; Altucci, L; Andrews, D; Annicchiarico-Petruzzelli, M; Baehrecke, EH; Bazan, NG; Bertrand, MJ; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Bredesen, DE; Brenner, C; Campanella, M; Candi, E; Cecconi, F; Chan, FK; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, KM; Di Daniele, N; Dixit, VM; Dynlacht, BD; El-Deiry, WS; Fimia, GM; Flavell, RA; Fulda, S; Garrido, C; Gougeon, ML; Green, DR; Gronemeyer, H; Hajnoczky, G; Hardwick, JM; Hengartner, MO; Ichijo, H; Joseph, B; Jost, PJ; Kaufmann, T; Kepp, O; Klionsky, DJ; Knight, RA; Kumar, S; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lugli, E; Madeo, F; Malorni, W; Marine, JC; Martin, SJ; Martinou, JC; Medema, JP; Meier, P; Melino, S; Mizushima, N; Moll, U; Muñoz-Pinedo, C; Nuñez, G; Oberst, A; Panaretakis, T; Penninger, JM; Peter, ME; Piacentini, M; Pinton, P; Prehn, JH; Puthalakath, H; Rabinovich, GA; Ravichandran, KS; Rizzuto, R; Rodrigues, CM; Rubinsztein, DC; Rudel, T; Shi, Y; Simon, HU; Stockwell, BR; Szabadkai, G; Tait, SW; Tang, HL; Tavernarakis, N; Tsujimoto, Y; Vanden Berghe, T; Vandenabeele, P; Villunger, A; Wagner, EF; Walczak, H; White, E; Wood, WG; Yuan, J; Zakeri, Z; Zhivotovsky, B; Melino, G; Kroemer, G Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.
Cell Death Differ. 2015; 22(1):58-73 Doi: 10.1038/cdd.2014.137 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jilg, S; Reidel, V; Muller-Thomas, C; Hockendorf, U; Huberle, C; Peschel, C; Oostendorp, RA; Gotze, KS; Jost, PJ MCL-1 conveys resistance to ABT-199 in primary MDS samples
ONCOL RES TREAT. 2015; 38: 260-260.
Web of Science

 

** Tweedell, RE; Bergmann-Leitner, ES; Tao, DY; King, JG; Robinson, TM; Bingham, K; Lanar, DE; Jost, PJ; Boddey, JA; Dinglasan, RR OPTIMIZED PLASMODIUM FALCIPARUM HEPATOCYTE INFECTION MODEL FACILITATES DRUG AND VACCINE DEVELOPMENT
AM J TROP MED HYG. 2015; 93(4): 290-290.
Web of Science

 

2014

Originalarbeit (Zeitschrift)

** Tao, D; King, JG; Tweedell, RE; Jost, PJ; Boddey, JA; Dinglasan, RR The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion.
Mol Cell Proteomics. 2014; 13(5):1153-1164 Doi: 10.1074/mcp.M113.035584 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Wong, WW; Vince, JE; Lalaoui, N; Lawlor, KE; Chau, D; Bankovacki, A; Anderton, H; Metcalf, D; O'Reilly, L; Jost, PJ; Murphy, JM; Alexander, WS; Strasser, A; Vaux, DL; Silke, J cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner.
Blood. 2014; 123(16):2562-2572 Doi: 10.1182/blood-2013-06-510743 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Yabal, M; Müller, N; Adler, H; Knies, N; Groß, CJ; Damgaard, RB; Kanegane, H; Ringelhan, M; Kaufmann, T; Heikenwälder, M; Strasser, A; Groß, O; Ruland, J; Peschel, C; Gyrd-Hansen, M; Jost, PJ XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation.
Cell Rep. 2014; 7(6):1796-1808 Doi: 10.1016/j.celrep.2014.05.008 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fallbericht

** Schweneker, K; Clemm, C; Brügel, M; Souvatzoglou, M; Hermisson, M; Schmidt-Graf, F; Zimmer, C; Peschel, C; Jost, PJ Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature.
Exp Hematol Oncol. 2014; 3(16):29-29 Doi: 10.1186/2162-3619-3-29 (- Case Report) [OPEN ACCESS]
PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jost, PJ; Yabal, M; Adler, H; Knies, N; Gross, C; Damgaard, RB; Kanegane, H; Peschel, C; Strasser, A; Gross, O; Ruland, J; Gyrd-Hansen, M A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation
BLOOD. 2014; 124(21):
Web of Science

 

** Yabal, M; Muller, N; Adler, H; Knies, N; Gross, CJ; Damgaard, RB; Kanegane, H; Ringelhan, M; Kaufmann, T; Heikenwalder, M; Strasser, A; Gross, O; Ruland, J; Peschel, C; Gyrd-Hansen, M; Jost, PJ Aberrant TNF signalling in dendritic cells in the absence of XIAP contributes to X-linked lymphoproliferative disease (XLP-2) by exaggerated necroptosis
ONCOL RES TREAT. 2014; 37: 246-246.
Web of Science

 

2013

Originalarbeit (Zeitschrift)

** Damgaard, RB; Fiil, BK; Speckmann, C; Yabal, M; zur Stadt, U; Bekker-Jensen, S; Jost, PJ; Ehl, S; Mailand, N; Gyrd-Hansen, M Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling.
EMBO Mol Med. 2013; 5(8):1278-1295 Doi: 10.1002/emmm.201303090 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Venjakob, AJ; Vogt, S; Stöckl, K; Tischer, T; Jost, PJ; Thein, E; Imhoff, AB; Anetzberger, H Local cooling reduces regional bone blood flow.
J Orthop Res. 2013; 31(11):1820-1827 Doi: 10.1002/jor.22417
Web of Science PubMed FullText FullText_MUG

 

** Vogt, S; Venjakob, AJ; Stöckl, K; Tischer, T; Jost, PJ; Imhoff, AB; Thein, E; Anetzberger, H Evidence of an autoregulatory mechanism of regional bone blood flow at hypotension.
Arch Orthop Trauma Surg. 2013; 133(9):1233-1241 Doi: 10.1007/s00402-013-1801-y
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Gotze, K; Kolb, HJ; Peschel, C; Jost, PJ Resistance to apoptosis in high-risk myelodysplastic syndrome can be overcome by pro-apoptotic drug treatment using ABT-737
LEUKEMIA RES. 2013; 37: S29-S30. Doi: 10.1016/S0145-2126(13)70065-1
Web of Science FullText FullText_MUG

 

** Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Kolb, HJ; Gotze, K; Peschel, C; Jost, PJ Pharmacologic intervention with the pro-apoptotic compound ABT-737 potently induces apoptosis in high-risk MDS/sAML bone marrow cells
ONKOLOGIE. 2013; 36: 124-125.
Web of Science

 

2012

Originalarbeit (Zeitschrift)

** Damgaard, RB; Nachbur, U; Yabal, M; Wong, WW; Fiil, BK; Kastirr, M; Rieser, E; Rickard, JA; Bankovacki, A; Peschel, C; Ruland, J; Bekker-Jensen, S; Mailand, N; Kaufmann, T; Strasser, A; Walczak, H; Silke, J; Jost, PJ; Gyrd-Hansen, M The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity.
Mol Cell. 2012; 46(6):746-758 Doi: 10.1016/j.molcel.2012.04.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Kaufmann, T; Strasser, A; Jost, PJ Fas death receptor signalling: roles of Bid and XIAP.
Cell Death Differ. 2012; 19(1):42-50 Doi: 10.1038/cdd.2011.121 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jost, PJ; Spinner, S; Kelly, G; Herold, M; Yabal, M; Strasser, A; Peschel, C The role of the anti-apoptotic Bcl-2 proteins Bcl-x(L) and Mcl-1 in survival of T-cell Non-Hodgkin's lymphoma
ONKOLOGIE. 2012; 35: 4-4.
Web of Science

 

2011

Abstract (Zeitschrift)

** Yabal, M; Damgaard, RB; Nachbur, U; Ruland, J; Peschel, C; Strasser, A; Silke, J; Gyrd-Hansen, M; Jost, PJ Inhibition of NOD2 signalling by mutations in the RING domain of XIAP contribute to development of X-linked lymphoproliferative syndrome
ONKOLOGIE. 2011; 34: 113-113.
Web of Science

 

2010

Originalarbeit (Zeitschrift)

** Vikstrom, I; Carotta, S; Lüthje, K; Peperzak, V; Jost, PJ; Glaser, S; Busslinger, M; Bouillet, P; Strasser, A; Nutt, SL; Tarlinton, DM Mcl-1 is essential for germinal center formation and B cell memory.
Science. 2010; 330(6007):1095-1099 Doi: 10.1126/science.1191793 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jost, PJ; Nachbur, U; Grabow, S; Huang, DC; Bouillet, P; Silke, J; Strasser, A; Kaufmann, T Anti-cancer SMAC-mimetic compounds accelerate hepatocyte cell death upon FAS or TNF-alpha signalling
ONKOLOGIE. 2010; 33: 63-64.
Web of Science

 

Kommentar

** Jost, PJ; Kaufmann, T Cancer caused by too much apoptosis--an intriguing contradiction?
Hepatology. 2010; 51(4):1110-1112 Doi: 10.1002/hep.23514 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Originalarbeit (Zeitschrift)

** Jost, PJ; Grabow, S; Gray, D; McKenzie, MD; Nachbur, U; Huang, DC; Bouillet, P; Thomas, HE; Borner, C; Silke, J; Strasser, A; Kaufmann, T XIAP discriminates between type I and type II FAS-induced apoptosis.
Nature. 2009; 460(7258):1035-1039 Doi: 10.1038/nature08229 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Kaufmann, T; Jost, PJ; Pellegrini, M; Puthalakath, H; Gugasyan, R; Gerondakis, S; Cretney, E; Smyth, MJ; Silke, J; Hakem, R; Bouillet, P; Mak, TW; Dixit, VM; Strasser, A Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.
Immunity. 2009; 30(1):56-66 Doi: 10.1016/j.immuni.2008.10.017 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Strasser, A; Jost, PJ; Nagata, S The many roles of FAS receptor signaling in the immune system.
Immunity. 2009; 30(2):180-192 Doi: 10.1016/j.immuni.2009.01.001 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Meeting Report

** Bianchi, K; Jost, PJ; Kaufmann, T; Rutkowski, R International EMBO Workshop on 'Model Organisms in Cell Death Research', Obergurgl (Austria).
Cell Death Differ. 2009; 16(8):1180-1183 Doi: 10.1038/cdd.2009.60 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Originalarbeit (Zeitschrift)

** Jost, PJ; Weiss, S; Ferch, U; Gross, O; Mak, TW; Peschel, C; Ruland, J Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection.
J Immunol. 2007; 178(2):953-960 Doi: 10.4049/jimmunol.178.2.953 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Jost, PJ; Ruland, J Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
Blood. 2007; 109(7):2700-2707 Doi: 10.1182/blood-2006-07-025809
Web of Science PubMed FullText FullText_MUG

 

2005

Fallbericht

** Jost, PJ; Stengel, SM; Huber, W; Sarbia, M; Peschel, C; Duyster, J Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case report.
Int J Hematol. 2005; 82(4):310-311 Doi: 10.1532/IJH97.E0505 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Jost, PJ; Ferch, U; Weiss, S; Leeder, S; Gross, O; Mak, TW; Peschel, C; Ruland, J Functional and molecular analysis of maturation of thymocytes in Bcl10 or Malt1 deficient mice.
BLOOD. 2005; 106(11): 929A-929A.
Web of Science

 

2003

Fallbericht

** Nieder, C; Jost, PJ; Grosu, AL; Peschel, C; Molls, M Report of a male patient with brain metastases from breast cancer.
Breast. 2003; 12(5):345-347 Doi: 10.1016/s0960-9776(03)00109-7 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2001

Originalarbeit (Zeitschrift)

** Jost, PJ; Harbottle, RP; Knight, A; Miller, AD; Coutelle, C; Schneider, H A novel peptide, THALWHT, for the targeting of human airway epithelia.
FEBS Lett. 2001; 489(2-3):263-269 Doi: 10.1016/s0014-5793(00)02236-5 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum